Accessibility Menu
InVitro International logo

InVitro International(OTC) IVRO

Current Price$0.06
Market Cap$1.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-98%
5 Year-42%
1 Year+2%
1 Month-28%
InVitro International last closing stock price
MetricPriceDate
Last closeUSD 0.062026-07-24
InVitro International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-25.76%USD 0.082026-07-15
1 month-28.37%USD 0.092026-06-24
3 month-23.72%USD 0.082026-04-21
Year to date-32.11%USD 0.092025-12-30
1 year+1.83%USD 0.062025-07-18
3 year-12.71%USD 0.072023-07-25
5 year-41.81%USD 0.112021-07-23
Since inception-97.87%USD 2.881992-05-01

InVitro International Financials at a Glance

Market Cap

$1.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$827.73K

Net Income (TTM)

$100.90K

EPS (TTM)

$0.00

P/E Ratio

13.89

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$0.06

Volume

130

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.06

52-Week Range

$0.03 - $0.16

Estimated Earnings Date

N/A

IVRO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InVitro International

InVitro International is a specialized company focused on developing and supplying non-animal testing kits for various industries. Established in 1985 and based in Placentia, California, the company offers innovative solutions for assessing eye and skin irritation, as well as chemical corrosiveness.

Products and Services
  • Irritection Assay System for irritation testing
  • Corrositex for assessing chemical corrosiveness
  • Tailored technological support and independent laboratory services
Growth Outlook
  • Revenue increased to $206,840 in Q2 2026, up from $182,600 in Q1 2026
  • Net income rose to $17,555 in Q2 2026, reflecting strong operational performance
  • Current ratio of 12.37 indicates robust liquidity and financial health
Financial Highlights
  • Trailing twelve months (TTM) revenue of $1,020,000 demonstrates consistent demand
  • Net profit margin of 12.19% indicates effective cost management
  • Operating cash flow per share of $0.00067 shows positive cash generation
InVitro International operates in the medical diagnostics and research sector, providing essential testing solutions that align with growing regulatory demands for non-animal testing methods. The company's flagship products, the Irritection Assay System and Corrositex, cater to a diverse range of industries, including cosmetics, pharmaceuticals, and chemicals. Recent financial performance highlights a positive trajectory, with a notable increase in revenue and net income in the latest quarter. The strong current ratio suggests that the company is well-positioned to meet its short-term obligations, while the net profit margin reflects effective management of operational costs. Overall, InVitro International presents a compelling opportunity for investors interested in the healthcare sector, particularly in companies that prioritize ethical testing methods and demonstrate solid financial fundamentals.
AI Generated • Jul 12, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

5

CEO

W. Richard Ulmer

Website

www.invitrointl.com

Headquarters

Placentia, CA 92870, US

IVRO Financials

Key Financial Metrics (TTM)

Gross Margin

81.83%

Operating Margin

8.60%

Net Income Margin

12.19%

Return on Equity

6.05%

Return on Capital

4.48%

Return on Assets

5.05%

Earnings Yield

7.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.16M

Volume

130

Avg. Volume

3.80K

Financials (TTM)

Gross Profit

$677.31K

Operating Income

$71.19K

EBITDA

$97.60K

Operating Cash Flow

$14.84K

Capital Expenditure

-$3.08K

Free Cash Flow

$11.76K

Cash & ST Invst.

$1.22M

Total Debt

$256.07K

InVitro International Performance Analysis

InVitro International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 853,511-14.9%
20232023-09-30USD 792,628-7.1%
20242024-09-30USD 811,2902.4%
20252025-09-30USD 878,9378.3%
InVitro International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-3019.3%
Q42025-09-30-13.0%
Q12025-12-31-10.4%
Q22026-03-3113.3%
InVitro International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD 0.00-78.6%
20232023-09-30USD 0.00-88.9%
20242024-09-30USD 0.004400.0%
20252025-09-30USD 0.0117.8%
InVitro International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-06-30185.7%
Q42025-09-30-40.0%
Q12025-12-31-58.3%
Q22026-03-3160.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$206.84K

+5.3%

Gross Profit

$168.07K

+5.5%

Gross Margin

81.26%

N/A

Market Cap

$1.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$225.67K

N/A

Employees

6

N/A

Net Income

$17.56K

+14.1%

EBITDA

$15.89K

-8.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.22M

-2.2%

Total Debt

$256.07K

-18.5%

Accounts Receivable

$71.99K

+33.1%

Inventory

$181.90K

-7.4%

Long Term Debt

$188.60K

-26.3%

Short Term Debt

$67.47K

+16.1%

Return on Assets

5.05%

N/A

Return on Invested Capital

3.80%

N/A

Free Cash Flow

-$12.44K

+33.8%

Operating Cash Flow

-$10.76K

+42.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHMNSOHM, Inc.
$0.00+0.00%
PLSHPanacea Life Sciences Holdings, Inc.
$0.08+0.00%
MITIMitesco, Inc.
$0.06-14.29%
YBGJYubo International Biotech Limited
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
NUNu Holdings
$14.09-0.01%

Questions About IVRO

What is the current price of InVitro International?

InVitro International is trading at $0.06 per share.

What is the 52-week range for InVitro International?

Over the past 52 weeks, InVitro International has traded between $0.03 and $0.16.

How much debt does InVitro International have?

As of the most recent reporting period, InVitro International reported total debt of $256.07K.

How much cash does InVitro International have on hand?

InVitro International reported $1.22M in cash and cash equivalents in its most recent financial results.

What is InVitro International’s dividend yield?

InVitro International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services